For discussion: Live attenuated vaccines for group B meningococcus

Vaccine

Volumn 17, Issue 2, 1999, Pages 114-117

  Tang, Christoph ^a   Moxon, Richard ^a   Levine, Myron M ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b Center for Vaccine Development   (United States)

Author keywords

Attenuated; Group B; Meningococcus; Vaccine

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; LIVE VACCINE; MEMBRANE PROTEIN;

ANTIGENICITY; ARTICLE; EXPOSURE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; INTRANASAL DRUG ADMINISTRATION; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; STRAIN DIFFERENCE;

BACTERIAL VACCINES; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; SAFETY; VACCINES, ATTENUATED;

EID: 0032889653     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00163-7     Document Type: Article

References (30)

1. Scholten R.J., Poolman J.T., Valkenburg H.A., Bijlmer H.A., Dankert J., Caugant D.A. Phenotypic and genotypic changes in a new clone complex of Neisseria meningitidis causing disease in The Netherlands, 1958-1990. Journal of Infectious Diseases. 169(3):1994;673-676.
2. Cruz C., Pavez G., Aguilar E.et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiology and Infection. 105(1):1990;119-126.
3. Fischer M., Perkins B.A. Neisseria meningitidis serogroup B: emergence of the ET-5 complex. Seminars in Pediatric Infectious Diseases. 8(1):1997;50-56.
4. Sacchi C.T., Pessoa L.L., Ramos S.R.et al. Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex. Journal of Clinical Microbiology. 30(7):1992;1734-1738.
5. Anderson E.L., Bowers T., Mink C.M.et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infection and Immunity. 62(8):1994;3391-3395.
6. Lieberman J.M., Chiu S.S., Wong V.K.et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA. 275(19):1996;1499-1503.
7. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. Journal of Immunology. 138(12):1987;4402-4407.
8. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. ii:1983;355-357.
9. Diaz Romero J., Outschoorn I.M. Current status of meningococcal group B vaccine candidates: capsular or noncapsular? Clinical Microbiology Review. 7(4):1994;559-575.
10. Herbert M.A., Heath P.T., Mayon-White R.T. Meningococcal vaccines for the United Kingdom. Communications in Disease Report CDR Review. 5(9):1995;R130-R135.
11. Zollinger, W., New and Improved Vaccines Against Meningococcal Vaccines, 2nd edn. Marcel Dekker, New York, 1997.
12. Frasch C.E., Zollinger W.D., Poolman J.T. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Reviews in Infectious Diseases. 7(4):1985;504-510.
13. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus.I. The role of humoral antibodies. Journal of Experimental Medicine. 129(6):1969;1307-1326.
14. Jones D.M., Kaczmarski E.B. Meningococcal infections in England and Wales: 1994. Communications in Disease Report CDR Review. 5(9):1995;R125-R130.
15. Gold R., Goldschneider I., Lepow M.L., Draper T.F., Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. Journal of Infectious Diseases. 137(2):1978;112-121.
16. Reller L.B., MacGregor R.R., Beaty H.N. Bactericidal antibody after colonization with Neisseria meningitidis. Journal of Infectious Diseases. 127(1):1973;56-62.
17. Mel D., Gangarosa E.J., Radovanovic M.L., Arsic B.L., Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bulletin of the World Health Organisation. 45(4):1971;457-464.
18. Mel D.M., Arsic B.L., Nikolic B.D., Radovanic M.L. Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bulletin of the World Health Organisation. 39(3):1968;375-380.
19. Mel D.M., Arsic B.L., Radovanovic M.L., Litvinjenko S.A. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiologica Academy of Science Hungary. 21(1/2):1974;109-114.
20. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., Bernstein D.I., Hayden F.G., Kotloff K., Zangwill K., Lacuzio D., Wolff M. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 338(20):1998;1405-1412.
21. Tacket C.O., Sztein M.B., Losonsky G.A.et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infection and Immunity. 65(2):1997;452-456.
22. Hohmann E.L., Oletta C.A., Killeen K.P., Miller S.I. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. Journal of Infectious Diseases. 173(6):1996;1408-1414.
23. Haneberg, B., Dalseg, R., Haugen, I.L., et al., Prospects for a nasal vaccine against group B meningococcal disease. Tenth International Pathogenic Neisseria Conference, Baltimore, USA. 1996, Abstr. 47, pp. 152-153.
24. Bone R.C. Gram-negative sepsis: a dilemma of modern medicine. Clinical Microbiology Review. 6(1):1993;57-68.
25. Nadel S., Newport M.J., Booy R., Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. Journal of Infectious Diseases. 174(4):1996;878-880.
26. Westendorp R.G., Langermans J.A., Huizinga T.W.et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. i:1997;170-173.
27. Feil E., Zhou J., Maynard Smith J., Spratt B.G. A comparison of the nucleotide sequences of the adk and recA genes of pathogenic and commensal Neisseria species: evidence for extensive interspecies recombination within adk. Journal of Molecular Evolution. 43(6):1996;631-640.
28. Levine M.M., Kaper J.B., Herrington D.A.et al. Safety, immunogenicity and efficacy in man of recombinant live oral cholera vaccines. Lancet. ii:1988;467-470.
29. Moxon E.R., Rainey P.B., Nowak M.A., Lenski R.E. Adaptive evolution of highly mutable loci in pathogenic bacteria. Current Biology. 4(1):1994;24-33.
30. Cartwright K.A., Stuart J.M., Jones D.M., Noah N.D. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiology and Infection. 99(3):1987;591-601.